Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551864 | 0.77 | SLC22A2 (0.30) | SLC22A2SLC22A1GRIN2DGRIN3BLMNA | |
| Hydrochloric Acid SCHEMBL11302602 | 0.76 | LMNA (0.41) | SLC22A2SLC22A1GRIN2DGRIN3BLMNA | |
| SCHEMBL641692 | 0.76 | — | — | |
| SCHEMBL4543539 | 0.72 | THRB (0.37) | — | |
| SCHEMBL14798101 | 0.69 | THRB (0.32) | — | |
| SCHEMBL3846377 | 0.65 | GRIN2D (0.35) | SLC22A2SLC22A1GRIN2DGRIN3BLMNA | |
| SCHEMBL150989 | 0.63 | HSD11B1 (0.39) | — | |
| SCHEMBL2745866 | 0.63 | SLC22A2 (0.33) | SLC22A2SLC22A1GRIN2DGRIN3BLMNA | |
| SCHEMBL1939322 | 0.61 | — | — | |
| SCHEMBL3418491 | 0.61 | GRIN2D (0.33) | SLC22A2SLC22A1GRIN2DGRIN3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | claimed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010015415-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | SLC22A2 4789/4885SLC22A1 4750/4885GRIN2D 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.